Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Eur Neuropsychopharmacol
; 74: 15-21, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37148637
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Substance-Related Disorders
/
Depressive Disorder, Major
/
Drug-Related Side Effects and Adverse Reactions
/
Depressive Disorder, Treatment-Resistant
/
Ketamine
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Eur Neuropsychopharmacol
Journal subject:
PSICOFARMACOLOGIA
Year:
2023
Document type:
Article